Enanta Pharmaceuticals
ENTA
148 hedge funds and large institutions have $824M invested in Enanta Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 52 increasing their positions, 40 reducing their positions, and 14 closing their positions.
150% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 14
38% more capital invested
Capital invested by funds: $598M → $824M (+$226M)
30% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 40
17% more funds holding
Funds holding: 127 → 148 (+21)
6.43% more ownership
Funds ownership: 66.95% → 73.38% (+6.4%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$25.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$13.5M |
| 3 |
Millennium Management
New York
|
+$11.1M |
| 4 |
First Manhattan
New York
|
+$6.87M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$5.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$8.59M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$7.86M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$7.85M |
| 4 |
KAM
Krensavage Asset Management
New York
|
-$7.36M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.68M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Citadel Advisors
Miami,
Florida
| – | -$316K | -6,310 | Closed |
|
152
SG Americas Securities
New York
| – | -$265K | -5,662 | Closed |
|
|
EMG
153
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$257K | -5,500 | Closed |
|
|
CCIA
154
Campbell & Co Investment Adviser
Baltimore,
Maryland
| – | -$220K | -4,709 | Closed |
|
|
QT
155
Quantbot Technologies
New York
| – | -$98K | -2,110 | Closed |
|
|
PI
156
PineBridge Investments
New York
| – | -$82K | -1,772 | Closed |
|
|
FDCDDQ
157
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$46.8K | -1,000 | Closed |
|
158
SEI Investments
Oaks,
Pennsylvania
| – | +$150 | +3 | New |
|
159
AssetMark Inc
Concord,
California
| – | +$250 | +5 | New |
|
ENTA Hedge Fund Activity: Q4 2017 in Review
148 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2017, worth a combined $824M — up 38% from $598M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ENTA positions and 14 closed out — a net gain of 21 holders — while 52 added to existing stakes and 40 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $25.7M. The largest seller was Stonepine Capital Management, cutting an estimated $8.59M.
- 148 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2017, up from 127 in Q3 2017.
- Funds reported $824M of Enanta Pharmaceuticals stock for Q4 2017, up 38% quarter-over-quarter.
- 35 funds opened new Enanta Pharmaceuticals positions in Q4 2017 and 14 closed out, a net change of +21 holders.
- The largest Enanta Pharmaceuticals buyer in Q4 2017 was Farallon Capital Management, an estimated $25.7M added.
- The largest Enanta Pharmaceuticals seller in Q4 2017 was Stonepine Capital Management, an estimated $8.59M sold.
Based on aggregated 13F filings for Q4 2017.